

Epidemiology and Clinical Characteristics in Individuals with Confirmed SARS-CoV-2 Infection During the Early COVID-19 Pandemic in Saudi Arabia

Fatimah S. Alhamlan^{1,2,3*}, Reem S. Almaghrabi⁴, Edward B. Devol⁵, Anwar B. Alotaibi⁵, Saleh M. Alageel⁵, Dalia A. Obeid^{1,6}, Basem M. Alraddadi⁷, Sahar I. Althawadi³, Maysoun S. Mutabagani³, Ahmed A. Al-Qahtani^{1,2}

¹Department of Infection and Immunity, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

²College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

³Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

⁴Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

⁵Department of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

⁶National Health laboratory, Saudi Center for Disease Prevention and Control, Riyadh, Saudi Arabia

⁷Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia

Keywords: SARS-CoV-2, COVID-19, Epidemiology, COVID-19 Treatment Regimens

***Corresponding author.** Fatimah S. Alhamlan Tel.: 966 11 442 4365, Fax: 966 11 442 4519.

Email address: falhamlan@kfshrc.edu.sa

1 Abstract

2
3 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the
4 catastrophic coronavirus disease 2019 (COVID-19) global pandemic. This study aimed to
5 provide epidemiologic and clinical characteristics of patients with confirmed COVID-19 in
6 Saudi Arabia and to determine whether characteristic profiles differ between patients who are
7 symptomatic vs. asymptomatic for the disease. The first 492 consecutive patients diagnosed with
8 SARS-CoV-2 infection at King Faisal Specialist Hospital and Research Centre in Saudi Arabia
9 between March and September 2020 were included in this study. An electronic case report form
10 developed using REDCap was used to collect data for each patient, including demographic
11 characteristics, virus exposure (travel history, and human and animal contact), vaccination
12 history, comorbidities, signs and symptoms, laboratory and radiographic reports, cardiac workup,
13 medications, treatment regimens, and patient outcome. This patient cohort was 54% male, with
14 20.4% aged more than 60 years, 19.9% aged 31 to 40 years, and 17% aged 41 to 50 years. Most
15 patients (79.2%) were symptomatic. Variables that significantly differed between symptomatic
16 and asymptomatic patients were age, blood oxygen saturation percentage, hemoglobin level,
17 lymphocyte count, neutrophil to lymphocyte (N/L) ratio, alanine aminotransferase (ALT) level,
18 and aspartate aminotransferase (AST) level. Asymptomatic patients were mostly younger, with
19 lower body mass index and ALT and AST levels but higher lymphocyte counts, N/L ratio, and
20 CD4, CD8, natural killer cell, IgG, and IgM levels. The median incubation period reported for
21 this cohort was 16 day, with upper and lower 95% quartiles of 27 and 10 days, respectively.
22 Factors associated with increased risk of mortality were age (older than 42 years) and
23 comorbidities, including specifically diabetes mellitus and hypertension. Patients who were not
24 given an antiviral regimen were associated with better prognosis than patients who received an
25 antiviral regimen (HR, 0.07; 95% CI, 0.011-0.25). Similar to countries worldwide, Saudi Arabia
26 has explored treatment options to save the lives of patients during the COVID-19 pandemic. Our
27 analyses will inform clinicians as well as policy makers to adopt the best strategies for SARS-
28 CoV-2 infection management and treatment options.

29 30 1. INTRODUCTION

31 Soon after the novel corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
32 2), emerged in Wuhan, China, in December 2019, its transmission from human to human
33 established a foothold worldwide [1, 2]. In Saudi Arabia, the first case of a SARS-CoV-2–
34 infected person was reported on March 2, 2020, a Saudi national who had returned to the country
35 from Iran [3]. As of July 11, 2021, there have been over 500,000 confirmed cases, 481,241
36 recovered cases, and 7963 deaths in Saudi Arabia [4]. The number of confirmed positive cases
37 had been escalating until now, July 2021, despite the country's strict control measures.

38
39 Viral epidemiology and clinical manifestation play critical roles in the battle against SARS-CoV-
40 2. Several studies have reported that patients infected with SARS-CoV-2 have primarily mild
41 symptoms and good prognosis. Overall, a small fraction of infected patients have been reported
42 to show severe pneumonia, pulmonary complications, acute respiratory distress syndrome, or
43 multiple organ failure or to have died [2]. As of July 11, 2021, worldwide statistics showed a
44 total of 185 million cases and 4 million deaths [5].

45
46 When the world was struck by this pandemic, hospitals leaders around the globe were
47 unprepared for the scope of the infection. Indeed, there is still much to learn to manage the

48 consequences of infections by this continually evolving virus. A lack of effective antiviral
49 medication led to numerous clinical trials of different regimens using available and repurposed
50 drugs to reach the best management of the disease caused by the virus, coronavirus 2019
51 (COVID-19). At King Faisal Specialist Hospital and Research Centre (KFSHRC), different
52 treatment options following international and local guidelines and recommendations were
53 offered to patients, including azithromycin, hydroxychloroquine (HCQ), azithromycin plus
54 HCQ, interferon, lopinavir/ritonavir, lopinavir/ritonavir plus ribavirin, and azithromycin plus
55 HCQ plus lopinavir/ritonavir [6-11].

56
57 The present study aimed to identify the epidemiologic characteristics, clinical features,
58 laboratory test results, treatment regimens, and clinical outcomes for patients admitted to
59 KFSHRC, a tertiary and referral hospital in Saudi Arabia, between March and September 2020,
60 and to determine whether patient profiles differed significantly between patients who were
61 symptomatic and those who were asymptomatic.

62 63 **2. MATERIALS AND METHODS**

64 **2.1 Ethical Considerations**

65 This study was conducted according to the World Medical Association Declaration of Helsinki
66 and conforms to the ethics recommendations of the Committee on Publication Ethics and the
67 International Committee of Medical Journal Editors. The study protocol was approved by the
68 Research Advisory Council (Ethics Committee) at KFSHRC (RAC #220 1047), which also
69 waived the requirement for obtaining informed patient consent because the risk to individuals
70 whose data were included in the study was minimal and the study used exclusively retrospective
71 deidentified administrative records.

72 73 **2.2 Data Collection**

74 Data regarding patients with confirmed COVID-19 (positive SARS-CoV-2 polymerase chain
75 reaction results) were obtained from KFSHRC electronic medical records from March to
76 September 2020. Data collectors were trained to ensure the completeness and accuracy of the
77 data collected. An electronic case report form was developed using REDCap (a secure and
78 flexible web-based clinical research data capture platform) that had over 500 data items for each
79 patient, including demographic characteristics, potential virus exposure (travel history and
80 human and animal contact), vaccination history, comorbidities, signs and symptoms, laboratory
81 and radiologic reports, cardiac workup, medication, treatment regimen, and patient outcome. An
82 unambiguous identification code was used that enabled identification of all data reported for
83 each patient. The risk to study participants was limited to the potential loss of confidentiality.
84 Appropriate measures were taken to prevent loss of participant confidentiality, including storage
85 of electronic case report forms in a secure manner and presentation of data without identification
86 of individual patients.

87 88 **2.3 Data and Statistical Analyses**

89 All collected data were stored and analyzed using SAS, version 9.4, software and GraphPad,
90 version 9.0 (Prisma). Inferential and descriptive statistics were conducted to assess the
91 epidemiologic and clinical manifestations of SARS-CoV-2 infections in Saudi Arabia. We
92 performed *t* tests and Mann-Whitney tests to assess continuous variables, and χ^2 tests to assess

93 categorical variables. Univariate and multivariate analyses were performed using Cox
94 proportional hazards regression models to identify factors associated with death from COVID-
95 19. The hazard ratio (HR) along with the 95% confidence interval (CI) are reported. All reported
96 *P*-values were two-tailed and were considered to be statistically significant at <0.05. Logistic
97 regression models were used to assess the prediction value of immunological parameters.
98

99 For estimating the time-varying reproduction number, we used the EpiEstim package, version
100 2.2.1, with R software, version 3.3 [12]. The model estimated the time-varying reproduction
101 number from the daily number of cases of COVID-19 reported at KFSHRC and an uncertain
102 generation time with a mean of 4.6 days and a standard deviation (SD) of 2.9 days based on other
103 studies [13]. We used a gamma distribution prior for the reproduction number with a mean of 2.6
104 and SD of 2.0 based on early estimates for the basic reproduction number (R0) from the initial
105 stages [14].
106

107 **3. RESULTS**

108 **3.1 Summary of Demographic Characteristics and Clinical Data**

109 Data from 492 patients were collected from the portal from March 10 to September 11, 2020.
110 Table 1 provides a summary of patient demographic and clinical characteristics for the cohort.
111 Of 492 patients, 54.0% were male. Most patients (20.4%) were older than 60 years, followed by
112 ages ranging from 31 to 40 years (20.0%) and from 41 to 50 years (17.9%). The highest
113 proportion of patients in this cohort received at KFSHRC were from Saudi Arabia (77.8%),
114 followed by the Philippines (29.4%), and India (22.4%). Of those from Saudi Arabia, the
115 majority were from Riyadh (79%), followed by Jeddah (15.1%). The clinical data indicated that
116 the majority of patients symptomatic for COVID-19 presented with a temperature lower than 38
117 °C (54.8%) and without a dry cough (51.6%). Only 21.2% reported myalgia fatigue, and 23.6%
118 had chest radiographs with indications of concern. Intensive care unit (ICU) admission was
119 received by 21.8% of the cohort, and 12.1% received mechanical ventilation. We found that
120 42.0% of patients presented with comorbidities, including 20.6% with diabetes and 24.4% with
121 hypertension. For patient outcomes on day 14 of hospitalization, 33.2% showed persistent
122 disease, 16.1% recovered, 8.4% were discharged from the hospital, and 1.5% died.
123

124 **3.2 Demographic and Clinical Characteristics of Symptomatic vs. Asymptomatic Patients**

125 The second aim of our study was to determine the demographic and clinical characteristics of
126 symptomatic vs. asymptomatic persons. Of 429 individuals in the cohort, 79.2% reported being
127 symptomatic and 20.7% being asymptomatic. A summary of the analysis assessing continuous
128 variables by symptomatic status is given in Table 2. Characteristics that were significantly
129 different between symptomatic and asymptomatic patients were age, blood oxygen saturation
130 percentage, hemoglobin level, lymphocyte level, the neutrophil to lymphocyte (N/L) ratio,
131 alanine aminotransferase (ALT) level, and aspartate aminotransferase (AST) level.
132 Asymptomatic patients were primarily younger, with lower body mass index and ALT and AST
133 levels, but higher N/L ratios and higher lymphocyte, CD4, CD8, natural killer cell, IgG, and
134 IgM levels.
135

136 Table 3 provides a summary of categorical data by symptom status. Many demographic and
137 clinical characteristics were significantly different between the two groups, including, age, sex,
138 smoking status, influenza vaccine receipt, comorbidities, diabetes, hypertension, chest

139 radiographic findings, pneumonia treatment, and outcome on days 7 and 14. The highest
140 proportion of asymptomatic patients were from age group 31–40 years and were men. Most
141 asymptomatic patients were nonsmokers, had received an influenza vaccine, and had no history
142 of comorbidities, including diabetes or hypertension.

143

144 **3.3 Variation in Disease Incubation Times**

145 The median incubation period reported in our population was 16 days (SD, 17 days), the upper
146 and lower 95% quartiles were 27 and 10 days, respectively. The incubation period differed
147 significantly only with age: patients 42 years or younger reported lower incubation times than
148 those older than 42 years. The incubation period did not differ significantly between any other
149 examined demographic or clinical variable, including the number of treatment regimens (Table
150 4).

151

152 **3.4 Demographical and Clinical Characteristics Associated with Death Due to COVID-19**

153 The epidemiologic and clinical factors associated with death among patients with COVID-19 are
154 summarized in Table 5. The only demographic characteristic that was statistically significantly
155 associated with death for patients with COVID-19 was being older than 42 years (HR, 10.32;
156 95% CI, 2.4-44.3) although the risk of death appeared higher for men than women, Saudi
157 nationals vs. non-Saudi persons, and individuals with vs. without obesity. Assessment of clinical
158 data indicated that being symptomatic or asymptomatic was not significantly associated with
159 higher risk of death, whereas having comorbidities in general was significantly associated with
160 higher risk of death (HR, 3.42; 95% CI, 1.24-12.1) as was specifically having diabetes mellitus
161 (HR, 3.9; 95% CI, 1.68-9.4) or hypertension (HR, 5.135; 95% CI, 2.2-12.5). None of the
162 common complications of COVID-19 (e.g., fever, myalgia fatigue, sore throat, and vomiting)
163 were significantly associated with death, although among these complications, higher risk of
164 poor prognosis was observed for patients with chest radiograph results indicating abnormalities,
165 followed by patients with dry cough and nausea. Regarding treatment options, patients who were
166 not given an antiviral regimen had better prognoses (HR, 0.07; 95% CI, 0.011-0.25) than patients
167 who received an antiviral regimen, followed by patients receiving interferon regimens.
168 Significant and high risk of death was associated with receipt of a combination therapy of
169 azithromycin, hydroxychloroquine, and lopinavir/ritonavir (HR, 149.6; 95% CI, 5.8-3808.4),
170 whereas lower risk of death was associated with receipt of a combination of two or more
171 therapies (HR, 2.7; 95% CI, 1.1-6.6). For receipt of a single treatment, among those examined,
172 lopinavir/ritonavir (HR, 19.28; 95% CI, 0.98-130.4) and azithromycin (HR, 3.5; 95% CI, 0.819-
173 10.4) were associated with the worst prognosis. Patients receiving pneumonia treatment were
174 associated with poor prognosis (HR, 9.1; 95% CI, 3.28-32.3), and patients receiving mechanical
175 ventilation had the second highest HR (HR, 90; 95% CI, 18.4-1624.2).

176

177 **3.5 Association of Immunological Factors with Patient Outcomes, Symptoms, and 178 Treatment Regimen**

179 Using multivariate Cox regression, we evaluated white blood cell (WBC), absolute lymphocyte,
180 and neutrophil counts and the NTL ratio as factors potentially associated with patient outcomes
181 and with type of treatment regimen. The values of these factors were obtained from patients after
182 they received a diagnosis of COVID-19. If a univariate model indicated that a factor was
183 significantly associated with patient outcome, we pursued additional testing for treatment type.

184

185 The results of a univariate Cox regression assessing WBC count indicated a significant
186 association with patient outcome ($\chi^2=11.9$, $P=0.0005$). The multivariate model testing treatment
187 types showed significance for all treatment types ($P<0.05$). For patients receiving
188 lopinavir/ritonavir treatment alone, the HR was significant (HR=35.3; 95% CI, 1.7-312.4),
189 whereas the HR for WBC count was 1.2 (95% CI, 1.1-1.3). The other significant HR was for
190 receipt of combination therapy with lopinavir/ritonavir, HCQ, and azithromycin (HR=154.5;
191 95% CI, 5.9-4013). For Patients receiving treatment with HCQ or azithromycin alone or with the
192 combination of HCQ and azithromycin or with interferon or for pneumonia, HRs were not
193 statistically significant ($P>0.05$).

194
195 A univariate cox regression model assessing the association of lymphocyte count with patient
196 outcome showed no significance ($\chi^2=0.39$, $P=0.53$). In addition, none of the multivariate models
197 were significant ($P>0.05$). Similarly, none of the models indicated an association with the NTL
198 ratio.

199
200 By contrast, for the neutrophil count, a univariate cox regression model assessing the association
201 with patient outcome was statistically significant ($\chi^2=6.7$, $P=0.0092$). The multivariate models
202 assessing an association with treatment types were significant for all treatment types ($P<0.05$).
203 However, the only significant treatment factors were lopinavir/ritonavir and the combination of
204 HCQ, azithromycin, and lopinavir/ritonavir. For patients receiving lopinavir/ritonavir treatment
205 alone, the HR was significant (HR=23.5; 95% CI, 1.1-196), whereas the neutrophil HR was 1.3
206 (95% CI, 1.1-1.5). For patients receiving the combination therapy, the HR was significant (HR,
207 92.8; 95% CI, 3.6-2348), whereas the neutrophil HR was 1.3 (95% CI, 1.1-1.5). For patients
208 receiving HCQ treatment, interferon treatment, any two-drug combination therapy, or pneumonia
209 treatment, the HRs were not significant ($P>0.05$).

210
211 We also evaluated models assessing associations of levels of immunological factors with patient
212 symptom status. Neither the WBC levels nor the neutrophil count were associated with patient
213 symptoms status. An immunological parameter that was significantly associated with patient
214 symptom status was the NTL ratio ($\chi^2=17.3$, $P<0.0001$); higher NTL ratios were correlated with
215 symptomatic disease (OR=0.6, 95% CI: 0.4-0.8). There was also a significant association
216 between patient symptom status and lymphocyte levels alone ($F=17.9$, $P<0.0001$; $R^2=0.058$);
217 higher WBC count was correlated with asymptomatic disease.

218
219 We evaluated the use of a mechanical ventilator as a proxy for the severity of disease and found
220 that it was significantly associated with the NTL ratio ($\chi^2=14.9$, $P<0.0001$, OR=1.2, 95% CI:1.1-
221 1.3), with higher NTL ratios correlating with severe disease. Similarly, higher WBC counts
222 ($\chi^2=42.9$, $P<0.0001$, OR=1.4, 95% CI:1.2-1.6) and higher neutrophil counts ($\chi^2=28.5$, $P<0.0001$,
223 OR=1.5, 95% CI:1.3-1.8). were correlated with greater disease severity. Although higher
224 lymphocyte levels appeared to be associated with less severe disease, the association was not
225 significant ($\chi^2=2.3$, $P=0.09$).

226
227 For patient outcomes, the model assessing the association of the WBC count ($\chi^2=13.3$, $P=0.003$,
228 OR=1.2, 95% CI:1.2-1.4) and that assessing the level of neutrophils ($\chi^2=11.0$, $P=0.0009$,
229 OR=1.4, 95% CI=1.4-1.7). were significant, with higher levels correlated with patient death.
230 However, neither the NTL ratio nor lymphocyte level was associated with patient death. Figure 2
231 shows the distribution of the immunological factors by disease severity and tested by the Mann-
232 Whitney test. Three multilevel logistic models were assessed with all immunological parameters,

233 and they were all significant predictor for patient's outcome, or severity or symptoms together
234 (P<0.005).

235
236 A multivariate model using multilevel regression was used to assess the association of
237 immunological factors with the incubation period. The lymphocyte count with age was the only
238 factor significantly associated with the incubation period (F=4.8, P=0.009). Neutrophil and WBC
239 counts and the NTL ratio were not associated.

240
241 **3.6 Reproduction Number Estimations and Predicting COVID-19 in Riyadh**
242 We estimated the instantaneous temporal effective reproduction number (R_t) using the EpiEstim
243 package and modeled it using a gamma distribution. For 155 days, confirmed COVID-19 cases
244 were detected at KFSHRC. Figure 3 shows the summary of the incidence and R values over
245 time. The average value for R from March 11 to August 10, 2020, was 1.21. In March, R
246 averaged 1.94, decreasing in April to 0.81, but increasing in May to 2.24, before decreasing in
247 June to 1.07 and in July to 0.92. The highest value of R was found in May, which is when the
248 government implemented strict lockdown protocols to substantially decrease the number of
249 confirmed COVID-19 cases in June and July, accompanied by a significant decrease in the value
250 of R. In August, a significant decrease in cases was observed followed by an increased risk of R
251 followed its mean values reported. We also estimated the effective reproduction number over
252 time in Saudi Arabia overall. The pattern across the entire country was similar to that estimated
253 for KFSHRC (Figure 4). However, R peaked at a national level in March then decreased in May
254 after the lockdown and kept decreasing in June and July. The average value of R in Saudi Arabia
255 between March and July was 1.23.

256 257 **4. DISCUSSION**

258
259 KFSHRC is a tertiary care hospital in Riyadh, Saudi Arabia, that typically provides specialized
260 care for cancer, organ transplantation, and patients who are immunocompromised in addition to
261 offering other medical specialties. However, to increase treatment capacity for Saudi Arabia
262 during the pandemic, KFSHRC allowed access to COVID-19 patients when it is needed. The
263 first case was admitted in March 2020. By investigating the demographic and clinical
264 characteristics of the first 492 patients with confirmed COVID-19, our study found that the
265 number of male patients was higher (54%) than female patients (46%), consistent with several
266 studies reporting from various parts of the world and indicating that men have higher morbidity
267 and mortality associated with COVID-19 than women [15-17]. The male vs. female differences
268 may be attributable to biological differences, including of the immune system, which impacts the
269 body's ability to fight an infection, including SARS-2-CoV-2. It has been reported that women
270 are more resistant to infections than men, and this is potentially mediated by several factors,
271 including different sex hormone levels and higher expression of coronavirus receptors
272 (angiotensin-converting enzyme, ACE receptors) in men but also lifestyle aspects, such as higher
273 levels of smoking and drinking among men compared with women [17]. Another vulnerability
274 factor observed in our study was age, with the highest percentage of patients with confirmed
275 COVID-19 being older than 60 years (20.4%), followed by patients aged 31 to 40 years (19.9%)
276 and those aged 41 to 50 years (17%), a finding consistent with several other studies. There is
277 evidence that the susceptibility to COVID-19 and the increased mortality risk in older people is
278 linked to frailty [18]. Regarding clinical characteristics, we found that most symptomatic patients
279 did not present with fever higher than 38 °C (54.8%) or dry cough (51.6%), and only 21%
280 reported myalgia fatigue and 23.6% had abnormal findings on chest radiography. The latter

281 finding was expected because COVID-19 may cause pneumonia that manifests clinically even in
282 asymptomatic patients [19].

283 Among 492 patients, 21% were admitted in ICU attention, and 12% received mechanical
284 ventilation. Approximately 42% of patients had comorbidities, including 20% with diabetes and
285 24% with hypertension. These results agree with a recent study from Spain in which they
286 retrospectively described 49 consecutive patients admitted to the internal medicine hospital ward
287 for COVID-19 infection and found a significant association between diabetes and the need for
288 admission to the ICU [20]. One of the largest studies of this type, conducted in 138 hospitals in
289 France, Belgium, and Switzerland and including over 4000 patients critically ill with COVID-19
290 admitted to an ICU, reported that patients who were older or had diabetes or obesity were at the
291 highest risk of mortality [21]. In addition, our data showed patient outcomes at day 14 included
292 persistent disease (33%), recovered (16%), discharged (8.4%) or death (1.5%). Our work also
293 investigated variations in incubation time and its association with different variables. We found
294 that the median incubation period reported in our population was 16 days (SD, 17 days), the
295 upper 95% quartile was 27 days, and the lower quartile was 10 days. The incubation period was
296 significantly associated only with age, with younger patients reporting a lower incubation period.
297 Other investigated variables were not significantly associated with the incubation period. A
298 systematic review and meta-analysis was recently published evaluating epidemiologic
299 parameters to determine transmission and incubation dynamics [22]. For more than 23 studies
300 combined, the mean incubation period of COVID-19 ranged from 4.8 to 9 days.

301
302 The present study determined whether patient profiles differed significantly for those who were
303 symptomatic vs. asymptomatic. In a total of 429 patients, 79.2% reported having symptoms, and
304 20.7% reported being asymptomatic. Not every asymptomatic patient went to the hospital to be
305 checked for the presence of SARS-CoV-2, which may explain the discrepancy between mild vs.
306 severe patient outcomes. According to the WHO, most people infected with the SARS-CoV-2
307 virus will experience mild to moderate respiratory illness and recover without requiring special
308 treatment; older people, and those with underlying medical problems, such as diabetes, chronic
309 respiratory disease, cardiovascular disease, and cancer, are more likely to develop serious illness
310 [23]. The age group and sex having the highest proportions of asymptomatic patients were 31-to-
311 40-year-olds and males. Compared with symptomatic patients, asymptomatic patients were
312 younger, nonsmokers, received an influenza vaccine, had no history of comorbidities, including
313 diabetes or hypertension, and had lower BMI, ALT, and AST levels. Asymptomatic patients also
314 had a higher NTL ratio and higher lymphocyte, CD4, CD8, natural killer cell, IgG, and IgM
315 levels.

316
317 This study reported the most important epidemiologic and clinical factors associated with
318 mortality in a cohort of patients with COVID-19. Our data showed that age and comorbidities
319 were significantly associated with higher risk of death in this cohort, with both diabetes mellitus
320 and hypertension associated with higher risk of death. Previous studies have shown that
321 populations over 65 years old with comorbidities such as diabetes or hypertension have higher
322 mortality rates in COVID-19 cases. The largest study of COVID-19 cases from China (72,314
323 cases) showed increased incidence of mortality among patients with diabetes and COVID-19
324 (2.3% without diabetes vs. 7.3% with the disease) [24]. Other studies from the United States,
325 Italy, and China have reported that the diabetic population is at greater risk not only for disease
326 complications but also for infection susceptibility [25].

327

328 Although an effective antiviral treatment for COVID-19 is not currently available, some
329 repurposed medications have been proposed for use at KFSHRC. We observed different patient
330 outcomes associated with each treatment regimen. Patients who did not receive an antiviral
331 regimen had better prognoses, followed by patients receiving an interferon regimen. A
332 significant and high HR was observed for patients receiving a combination therapy of
333 azithromycin, hydroxychloroquine, and lopinavir/ritonavir, and a lower HR was observed for
334 patients receiving a combination therapy of two or more drugs. Among patients who received
335 only a single drug regimen, those receiving lopinavir/ritonavir or azithromycin had the worst
336 prognosis. Our findings are consistent with the reported international data and clinical trials [26-
337 29]. Patients receiving pneumonia treatment had poor prognosis overall, and patients receiving
338 mechanical ventilation had also the second-highest rate. We concluded from our data on the
339 treatment regimens that azithromycin, hydroxychloroquine, and lopinavir/ritonavir were not
340 effective treatment for COVID 19, and this is consistent with previous studies and the solidarity
341 trial [30, 31]

342
343 There are limitations in the current database and the main limitation is that this retrospective
344 study was conducted during the early COVID-19 pandemic where various effective interventions
345 were not assessed such as dexamethasone, IL6 inhibitors, Jak inhibitors and Remdesvir.

346 347 **Conclusion**

348 This study reports significant differences between patients symptomatic and asymptomatic for
349 COVID-19 in a cohort with a relatively large number at a Saudi tertiary care hospital, improving
350 the understanding of the epidemiologic and clinical features associated with SARS-CoV-2
351 infection. This study also assesses treatment regimens used early in the COVID-19 pandemic to
352 inform scientific and medical databases and future clinical use and research.

353 354 **Contribution to the Field**

355 This work provides epidemiologic and clinical characteristics data from patients in Saudi Arabia
356 with confirmed SARS-COV-2 infection to inform treatment regimens and case management.
357 Scarce studies from Saudi Arabia have highlighted case management and treatment regimens,
358 especially for symptomatic vs. asymptomatic patients. The data provided here were obtained
359 from a comprehensive database developed in-house for King Faisal Specialist Hospital and
360 Research Centre, a single-center, tertiary and referral care hospital. We created the electronic
361 medical records database to collect from each patient their demographic characteristics, virus
362 exposure (travel history, and human and animal contact), vaccination history, comorbidities,
363 signs and symptoms, laboratory and radiographic reports, cardiac workup, medications,
364 treatment regimens, and outcome. The database continues to be used for all patients with
365 confirmed SARS-COV-2 infection. Here, we describe our analyses of the demographic and
366 clinical characteristic data obtained from the first 492 consecutive patients at the hospital
367 diagnosed with SARS-CoV-2 infection. These findings provide insights on the epidemiologic
368 and clinical characteristics and case management of patients in Saudi Arabia with confirmed
369 SARS-COV-2 infection to inform future treatment regimens worldwide.

370 371 372 373 **Conflict of Interests**

374 The authors declare that the research was conducted in the absence of any commercial or
375 financial relationships that could be construed as a potential conflict of interest.

376

377 **Author Contributions**

378 FA is the principal investigator of this study. RA and ED are co-principle investigators who
379 helped in the study design and validation. BA, SA, MM, and AA are physicians and clinical
380 scientists who reviewed medical charts and helped in clinical data interpretation. DO performed
381 the statistical analysis. AA and SA built the database, trained the data collectors, and oversaw
382 data collection and data quality. All authors helped in writing and reviewing the manuscript. In
383 addition, all authors read and approved the final manuscript.

384

385 **Funding**

386 This work was fully funded by a King Faisal Specialist Hospital and Research Centre COVID-19
387 grant (KFSHRC; RAC #220 1047)

388

389 **Acknowledgements**

390 We thank the KFSHRC higher administration for their full support during the pandemic. We also
391 thank the data collection team who is managing the hospital database [Haya Alajlan, Ruba
392 Aldossary, Samar Almogbel, Noura Alqahtani, Shatha Alshammari, Rahaf Al-Rashoud, Sanaa
393 Al-Ali, Hadeel Al-Bedewi, Leen Al-Hogbani, Fai Al-Khathlan, Najla Al-Orayyidh, Noura Al-
394 Zannan, Raneem Al-Zeer, Shatha Barajaa, and Ishraq Rajeh].

395

396

397 **Data Availability Statement**

398 The raw data supporting the conclusions of this article will be shared by the authors when
399 requested.

400

401

402 **References**

403

- 404 [1] N. Zhu *et al.*, "A Novel Coronavirus from Patients with Pneumonia in China, 2019," *N*
405 *Engl J Med*, vol. 382, no. 8, pp. 727-733, Feb 20 2020.
- 406 [2] N. Chen *et al.*, "Epidemiological and clinical characteristics of 99 cases of 2019 novel
407 coronavirus pneumonia in Wuhan, China: a descriptive study," *Lancet*, vol. 395, no.
408 10223, pp. 507-513, Feb 15 2020.
- 409 [3] D. A. Obied, F. S. Alhamlan, A. A. Al-Qahtani, and M. N. Al-Ahdal, "Containment of
410 COVID-19: the unprecedented response of Saudi Arabia," *J Infect Dev Ctries*, vol. 14,
411 no. 7, pp. 699-706, Jul 31 2020.
- 412 [4] MOH, "<https://covid19.moh.gov.sa/> " 2021.
- 413 [5] W. Stat, "COVID-19 CORONAVIRUS PANDEMIC STATISTICS," 2021.
- 414 [6] S. M. o. Health, "Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-
415 19," 2020.
- 416 [7] J. Gao, Z. Tian, and X. Yang, "Breakthrough: Chloroquine phosphate has shown apparent
417 efficacy in treatment of COVID-19 associated pneumonia in clinical studies," *Biosci*
418 *Trends*, vol. 14, no. 1, pp. 72-73, Mar 16 2020.

- 419 [8] M. Wang *et al.*, "Remdesivir and chloroquine effectively inhibit the recently emerged
420 novel coronavirus (2019-nCoV) in vitro," *Cell Res*, vol. 30, no. 3, pp. 269-271, Mar
421 2020.
- 422 [9] B. Cao *et al.*, "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-
423 19," *N Engl J Med*, vol. 382, no. 19, pp. 1787-1799, May 7 2020.
- 424 [10] E. K. Snow *et al.*, "Creation and maintenance of a table for assessment of evolving
425 evidence for COVID-19-related treatments," *Am J Health Syst Pharm*, vol. 78, no. 2, pp.
426 154-157, Jan 5 2021.
- 427 [11] I. F. Hung *et al.*, "Triple combination of interferon beta-1b, lopinavir-ritonavir, and
428 ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label,
429 randomised, phase 2 trial," *Lancet*, vol. 395, no. 10238, pp. 1695-1704, May 30 2020.
- 430 [12] A. Cori, N. M. Ferguson, C. Fraser, and S. Cauchemez, "A new framework and software
431 to estimate time-varying reproduction numbers during epidemics," *Am J Epidemiol*, vol.
432 178, no. 9, pp. 1505-12, Nov 1 2013.
- 433 [13] H. Nishiura, N. M. Linton, and A. R. Akhmetzhanov, "Serial interval of novel
434 coronavirus (COVID-19) infections," *Int J Infect Dis*, vol. 93, pp. 284-286, Apr 2020.
- 435 [14] S. Abbott, J. Hellewell, J. Munday, C. n. w. group, and S. Funk, "The transmissibility of
436 novel Coronavirus in the early stages of the 2019-20 outbreak in Wuhan: Exploring
437 initial point-source exposure sizes and durations using scenario analysis," *Wellcome
438 Open Res*, vol. 5, p. 17, 2020.
- 439 [15] W. J. Guan *et al.*, "Clinical Characteristics of Coronavirus Disease 2019 in China," *N
440 Engl J Med*, vol. 382, no. 18, pp. 1708-1720, Apr 30 2020.
- 441 [16] G. Onder, G. Rezza, and S. Brusaferro, "Case-Fatality Rate and Characteristics of
442 Patients Dying in Relation to COVID-19 in Italy," *JAMA*, vol. 323, no. 18, pp. 1775-
443 1776, May 12 2020.
- 444 [17] G. M. Bwire, "Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women?,"
445 *SN Compr Clin Med*, pp. 1-3, Jun 4 2020.
- 446 [18] S. Hagg *et al.*, "Age, Frailty, and Comorbidity as Prognostic Factors for Short-Term
447 Outcomes in Patients With Coronavirus Disease 2019 in Geriatric Care," *J Am Med Dir
448 Assoc*, vol. 21, no. 11, pp. 1555-1559 e2, Nov 2020.
- 449 [19] H. Shi *et al.*, "Radiological findings from 81 patients with COVID-19 pneumonia in
450 Wuhan, China: a descriptive study," *Lancet Infect Dis*, vol. 20, no. 4, pp. 425-434, Apr
451 2020.
- 452 [20] L. Fernandez Garcia, A. B. Puentes Gutierrez, and M. Garcia Bascones, "Relationship
453 between obesity, diabetes and ICU admission in COVID-19 patients," *Med Clin (Engl
454 Ed)*, vol. 155, no. 7, pp. 314-315, Oct 9 2020.
- 455 [21] C.-I. G. o. b. o. t. R. Network and C.-I. C. U. I. the, "Clinical characteristics and day-90
456 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study,"
457 *Intensive Care Med*, vol. 47, no. 1, pp. 60-73, Jan 2021.
- 458 [22] M. Alene, L. Yismaw, M. A. Assemie, D. B. Ketema, W. Gietaneh, and T. Y. Birhan,
459 "Serial interval and incubation period of COVID-19: a systematic review and meta-
460 analysis," *BMC Infect Dis*, vol. 21, no. 1, p. 257, Mar 11 2021.
- 461 [23] WHO, "Coronavirus," 2020.
- 462 [24] Z. Wu and J. M. McGoogan, "Characteristics of and Important Lessons From the
463 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
464 72314 Cases From the Chinese Center for Disease Control and Prevention," *JAMA*, vol.
465 323, no. 13, pp. 1239-1242, Apr 7 2020.

- 466 [25] L. Luzi and M. G. Radaelli, "Influenza and obesity: its odd relationship and the lessons
467 for COVID-19 pandemic," *Acta Diabetol*, vol. 57, no. 6, pp. 759-764, Jun 2020.
- 468 [26] M. Takla and K. Jeevaratnam, "Chloroquine, hydroxychloroquine, and COVID-19:
469 Systematic review and narrative synthesis of efficacy and safety," *Saudi Pharm J*, vol.
470 28, no. 12, pp. 1760-1776, Dec 2020.
- 471 [27] C. Axfors *et al.*, "Mortality outcomes with hydroxychloroquine and chloroquine in
472 COVID-19 from an international collaborative meta-analysis of randomized trials," *Nat*
473 *Commun*, vol. 12, no. 1, p. 2349, Apr 15 2021.
- 474 [28] R. C. Group, "Lopinavir-ritonavir in patients admitted to hospital with COVID-19
475 (RECOVERY): a randomised, controlled, open-label, platform trial," *Lancet*, Oct 5 2020.
- 476 [29] R. C. Group *et al.*, "Effect of Hydroxychloroquine in Hospitalized Patients with Covid-
477 19," *N Engl J Med*, vol. 383, no. 21, pp. 2030-2040, Nov 19 2020.
- 478 [30] W. H. O. S. T. Consortium *et al.*, "Repurposed Antiviral Drugs for Covid-19 - Interim
479 WHO Solidarity Trial Results," *N Engl J Med*, vol. 384, no. 6, pp. 497-511, Feb 11 2021.
- 480 [31] A. Di Castelnuovo *et al.*, "Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized
481 COVID-19 Patients: Findings From the Multicenter Italian CORIST Study," *Front Med*
482 (*Lausanne*), vol. 8, p. 639970, 2021.
- 483

484 **Figure legends**

485 Figure 1. Age group distribution of COVID-19 cases by symptom status (asymptomatic vs.
 486 symptomatic) shown as percentages. Most patients in this cohort with confirmed COVID-19
 487 were older than 60 years (19%); 21% of the cohort was asymptomatic, whereas 79% was
 488 symptomatic. The highest percentage of asymptomatic patients (5%) was observed in the age
 489 group of 30 to 39 years.

490
 491 Figure 2. Box plots of patient blood test results after diagnosis by illness severity as assessed by
 492 the need for mechanical ventilation (MV). A) White blood cell count by illness severity, with
 493 higher counts observed for more severe illness. B) Neutrophil absolute count by illness severity,
 494 with higher counts observed for more severe illness. C) Lymphocyte absolute count by illness
 495 severity, with higher counts observed for milder illness. D) Neutrophil to lymphocyte (NTL)
 496 ratio by illness severity, with higher ratios observed for more severe illness.

497
 498 Figure 3. Instantons reproduction number (R_t) estimated using the EpiEstim package and
 499 modeled using a gamma distribution. Cases were detected for 155 days at KFSHRC. The average
 500 R value from March 10 to August 11, 2020, was 1.21. The red line shows the average median of
 501 R; dashed red line, confidence intervals; green line, incidence of cases reported; gray area, the
 502 lockdown period; and blue line, $R=1$.

503
 504 Figure 4. The estimated instantons reproduction number (R_t), using EpiEstim package and model
 505 using gamma distribution. Cases were detected for 155 days in Saudi Arabia. The average R-
 506 value from March 10 to August 11, 2020, was 1.23. The red line shows the average median of R,
 507 the dashed red line shows the confidence intervals, while the green line shows the incidence of
 508 cases reported, the grey area represents the time of lockdown, while the blue line represents the
 509 $R=1$.

510
 511 **TABLES**

512
 513 Table 1. Demographic and clinical characteristics of 492 patients.

Characteristic	No. of patients	Percentage of total patients	χ^2 (P-value)
Age			16.23 (0.01)
<20	66	13.4	
21-30	61	12.4	
31-40	98	19.9	
41-50	88	17.9	
51-60	78	15.9	
>60	100	20.4	
Sex			3.1 (0.076)
Male	262	54.0	
Female	223	45.9	
Unknown	6	NA*	
Nationality			
Saudi	372	77.8	148 (<0.0001)
Non-Saudi	106	22.2	
Unknown	13	NA*	
Other nationalities			
Bangladesh	6	7.1	

British	2	2.4	
Canadian	1	1.2	
Egyptian	2	2.4	
Filipino	25	29.4	
Indian	19	22.4	
Jordanian	7	8.2	
Lebanese	1	1.2	
Nigerian	1	1.2	
Pakistani	9	10.6	
Sudanese	7	8.2	
Swiss	1	1.2	
Syrian	1	1.2	
Yemeni	1	1.2	
Saudi city or region			
Riyadh	377	79	3541 (0.0001)
Jeddah	72	15.1	
Eastern Region	10	2.1	
Ahsa	2	0.4	
Albaha	1	0.2	
Asir	2	0.4	
Hail	1	0.2	
Jazan	1	0.2	
Madinah	1	0.2	
Najran	3	0.6	
Northern Borders	3	0.6	
Tabouk	2	0.4	
Unknown	14	NA*	
Smoking status			223 (<0.0001)
Smoker	43	11.4	
Nonsmoker	333	88.6	
Unreported	115	NA*	
Pregnant			177 (<0.001)
Yes	11	5.02	
No	208	94.9	
Unreported	272	NA*	
HCW			32 (<0.0001)
Yes	110	23.2	
No	169	35.6	
Unknown	212	NA*	
BMI (kg/m²)			168 (<0.0001)
<18.5	166	49.3	
19-30	7	1.9	
25-30	56	15.9	
>30	122	34.8	
Unknown	140	NA*	
Body temperature >38 °C			261 (<0.001)
Yes	154	32.9	
No	257	54.8	
Not assessed	58	12.3	

Dry Cough			
Yes	152	32.1	126 (<0.001)
No	244	51.6	
Not assessed	77	16.3	
Runny Nose			
Yes	72	15.4	174 (<0.001)
No	289	61.7	
Not assessed	107	22.9	
Myalgia fatigue			
Yes	113	21.2	82 (<0.001)
No	248	53.1	
Not assessed	106	22.7	
Chest Radiograph			56 (<0.001)
Normal	231	49.6	
Abnormal	110	23.6	
Not assessed	125	26.8	
Intensive care unit			
Yes	100	21.8	222.2 (<0.001)
No	301	65.7	
Not assessed	33	NA*	
Mechanical ventilation			
Yes	55	12.1	327.5 (<0.001)
No	333	73.4	
Unknow	103	NA*	
Comorbidities			
Yes	206	41.9	12 (<0.0001)
No	285	58.0	
Diabetes mellitus			
Yes	101	20.5	170 (<0.0001)
No	390	79.4	
Hypertension			128 (<0.0001)
Yes	120	24.4	
No	371	75.6	
Outcome on day 14			
Recovered	65	16.1	220 (<0.001)
Death	6	1.5	
Discharge	34	8.4	
Persistent disease	134	33.2	
Not documented	252	NA*	
Travel to countries outside Saudi Arabia			218.9 (<0.0001)
Yes	31	6.5	
No	293	62.1	
Not reported	133	NA*	

514 Abbreviations: BMI, body mass index; HCW, health care worker.

515 *Not included in the statistical test.

516

517 Table 2. Continuous demographic and clinical characteristics assessed by symptomatic vs.

518 asymptomatic status.

Characteristic	Mean (SD)	t test or
----------------	-----------	-----------

	Asymptomatic (n=89)	Symptomatic (n=340)	Wilcoxon test (P-value)
Age (years)	35.4 (18.6)	45.1 (20.5)	4.1 (<0.0001)*
BMI (kg/m ²)	26.9 (6.9)	28.6 (7.3)	1.79 (0.074)
Respiratory Rate (breaths/min)	20.5 (4.5)	21.7 (6.4)	1.45 (0.075)
Heart rate (beats/min)	93.9 (14.9)	92.8 (18.6)	0.42 (0.67)
Systolic blood pressure (mm Hg)	126.9 (16.2)	128.1 (19.5)	0.53 (0.59)
Diastolic blood pressure (mm Hg)	77.5 (10.5)	75.8 (11)	1.15 (0.25)
Mean arterial blood pressure (mm Hg)	95.2 (11.6)	93.5 (14.4)	0.97 (0.33)
Oxygen Saturation (%)	97.4 (1.4)	96.2 (4.7)	3.58 (0.0004)*
Hemoglobin (g/L)	135.9 (20.6)	129.3 (22.9)	2.18 (0.03)*
Platelets (10 ⁹ /L)	238.0 (113.2)	213.6 (72.2)	1.73 (0.088)
White blood cell count (10 ⁹ /L)	5.6 (2.4)	5.9 (3.1)	0.59 (0.48)
Neutrophil count (10 ⁹ /L)	3.1 (1.9)	3.5 (2.1)	2.26 (0.024) ^{a*}
Lymphocyte (10 ⁹ /L)	1.9 (0.95)	1.4 (0.78)	3.72 (0.0002) ^{a*}
CD4 (mm ³)	584.6 (551.7)	523 (349)	0.29 (0.78)
Neutrophil to lymphocyte ratio	1.8 (1.1)	3.50 (3.2)	3.78 (0.0002) ^{a*}
CD8 (mm ³)	502.3 (285)	323.8 (257.6)	1.56 (0.126)
CD19 (mm ³)	240.6 (244)	153.7 (231)	0.91 (0.368)
NK (mm ³)	212 (132)	140.8 (128.2)	1.13 (0.31)
IgG (g/L)	13.1 (3.5)	11.1 (3.1)	1.42 (0.23)
IgM (g/L)	4.5 (9)	1.1 (0.57)	0.91 (0.40)
IgA (g/L)	2.56 (1.1)	2.56 (0.94)	0.02 (0.98)
ALT (U/L)	25.4 (24.9)	35.9 (44.1)	2.59 (0.01)*
AST (U/L)	24.7 (13.1)	39.9 (80.6)	2.90 (0.0004)*

519 Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body
 520 mass index; IG, immunoglobulin; NK, natural killer cells.

521 *Significant P-value less than 0.05.

522 ^aWilcoxon rank-sum test; distribution is not normal.

523

524 Table 3. Categorical demographic and clinical characteristics assessed by symptomatic vs.
 525 asymptomatic status

Characteristic	Patients, No. (%)		χ^2 (P-value)
	Asymptomatic (n=89)	Symptomatic (n=340)	
Age group, years (n=430)			
<20, n=51	17 (3.9)	34 (7.9)	15.1 (0.0009) *
21-30, n=52	12 (2.8)	40 (9.30)	
31-40, n=84	20 (4.6)	64 (14.8)	
41-50, n=83	16 (3.7)	67 (15.6)	
51-60, n=71	17 (3.9)	54 (12.3)	
>60, n=89	7 (1.6)	82 (19.1)	
Sex, n=430			
Male , n=236	59 (13.72)	177 (41.2)	5.9 (0.015)*
Female , n=194	30 (6.98)	164 (38.1)	
Nationality, n=423			

Saudi, n=326	70 (16.5)	256 (60.5)	1.14 (0.28)
Non-Saudi, N=97	16 (3.8)	81 (19.2)	
Smoking, n=362			
Smoker, n=43	15 (4.1)	28 (7.7)	5.69 (0.014)*
Nonsmoker, n=319	60 (16.5)	259 (71.5)	
Pregnancy, n=163			
Pregnant, n=10	3 (1.5)	7 (3.6)	1.67 (0.19)
Not pregnant, n=183	27 (13.99)	156 (80.8)	
Health Care worker, n=269			
Yes, n=109	25 (9.3)	84 (31.2)	0.07 (0.79)
No, n=160	39 (14.5)	121 (44.98)	
Received influenza vaccine (during the last 5 years), n=262			
Received, n=225	39 (14.9)	186 (70.9)	4.62 (0.032)*
Did not receive, n=37	12 (4.6)	25 (9.54)	
Comorbidities, n=430			13.4 (<0.0001)*
One or more, n=169	50 (11.63)	39 (9.1)	
None, n=261	119 (26.7)	222 (51.6)	
Diabetes mellitus, n=430			4.1 (0.044)*
Diagnosed with illness, n=97	13 (3.02)	84 (19.5)	
Not diagnosed, n=333	76 (17.7)	257 (59.8)	
Hypertension, n=430			10.1 (0.0015)*
Diagnosed with illness, n=115	12 (2.8)	11 (17.9)	
Not diagnosed, n=315	103 (23.9)	238 (55.4)	
BMI, n=291			1.17 (0.75)
<18, n=112	25 (8.6)	87 (29.9)	
19-30, n=5	1 (0.34)	4 (1.4)	
25-30, n=55	10 (3.4)	45 (15.6)	
>30, n=119	20 (6.9)	99 (34.02)	
Chest radiograph finding, n=417			32 (<0.0001) *
Normal, n=226	64 (15.4)	162 (38.9)	
Abnormal, n=108	2 (0.48)	106 (25.42)	
Not done, n=83	20 (4.8)	63 (15.11)	
Pneumonia treatment, n=328			
Yes, n=145	11 (2.7)	134 (32.6)	22.1 (<0.0001)*
No, n=266	72 (17.5)	194 (47.2)	
Outcome on day 7, n=392			9.5 (0.049)*
Recovered, n=21	6 (1.53)	15 (3.8)	
Death, n=1	0	1 (0.26)	
Discharged, n=18	6 (1.53)	12 (3.1)	
Persistent disease, n=266	38 (9.7)	228 (58.2)	
Not documented, n=86	21 (5.4)	65 (16.6)	
Outcome on day 14, n=358			
Recovered, n=63	17 (4.75)	46 (12.9)	10.7 (0.030)*
Death, n=6	0	6 (1.68)	
Discharged, n=33	9 (2.51)	24 (6.70)	
Persistent disease, n=132	15 (4.2)	117 (32.7)	
Not documented, n=124	23 (6.42)	101 (28.21)	
Blood Type, n=250			
A, n=71	12 (4.8)	59 (23.6)	3.04 (0.38)

B, n=37	9 (3.6)	28 (11.2)	
AB, n=8	0	8 (3.2)	
O, n=134	22 (8.8)	112 (44.8)	
RH status, n=250			
Rh- (n=27)	3 (1.20)	40 (16.0)	0.78 (0.37)
Rh+ (n=223)	24 (9.6)	183 (73.2)	
Blood culture, n=152			
Positive, n=15	0	15 (9.9)	
Negative, n=137	15 (9.9)	122 (80.3)	
Not tested			
Recovered at data collection, n=369			
Yes, n=149	52 (14.1)	197 (53.4)	3.8 (0.0503)
No, n=120	15 (4.1)	105 (28.5)	
Death, n=376			
Yes, n=22	1 (0.3)	21 (5.6)	2.8 (0.093)
No, n=354	66 (17.6)	288 (76.6)	

526 Abbreviation: BMI, body mass index.

527

528 Table 4. Incubation time differences by demographic or clinical characteristic or treatment
529 regimen

Characteristic	Incubation time, mean (SD), days	T test (P-value)
Age		
≤42	19.9 (20.2)	2.25 (<0.0001)*
>42	24.3 (20.2)	
Sex		
Male	21.1 (17.5)	0.44 (0.66)
Female	22.2 (17.2)	
Nationality		
Saudi	20.6 (16.8)	1.31 (0.097)
Non-Saudi	25.5 (19.2)	
Smoking status		
Smoker	18.5 (10.8)	0.45 (0.657)
Nonsmoker	19.8 (16.5)	
Symptom Status		
Symptomatic	20.9 (16.1)	
Asymptomatic	20.75 (20.5)	0.07 (0.94)
Treatment regimen		
One or none	22.85 (18.4)	1.06 (0.28)
More than two	20.2 (15.9)	
Comorbidities		
One or more	23.4 (19)	1.1 (0.27)
None	20.5 (16.15)	
Diabetes mellitus		
Diagnosed with illness	23.8 (15.6)	0.80 (0.43)
Not diagnosed	21.1 (17.1)	
Hypertension		
Diagnosed with illness	23.8 (25.6)	1.1 (0.29)
Not diagnosed	20.9 (23.7)	

530 *Significant P-value less than 0.05.

531
532 Table 5. Association of demographic and clinical characteristics and treatment regimen with
533 death in patients with confirmed COVID-19

Variable	Cox regression univariate model HR	95% Confidence interval	P-value
Sex			
Female	1(Ref)		
Male	1.56	0.67-3.66	0.30
Age			
≤42	1(Ref)		
>42	10.32	2.4-44.3	0.0017*
Nationality			
Saudi	1.93	0.557-12.2	0.37
Non-Saudi	1(Ref)		
BMI (kg/m²)			
≤30	1(Ref)		
>30	2.28	0.91-5.44	0.065
Symptom status			
Asymptomatic	1(Ref)		
Symptomatic	4.68	0.942-85	0.137
Comorbidities			
Reported	3.42	1.24-12.1	0.0293*
Not reported	1(Ref)		
Diabetes mellitus			
Reported	3.9	1.68-9.4	0.0015*
Not reported	1(Ref)		
Hypertension			
Reported	5.135	2.2-12.5	0.0002*
Not reported	1(Ref)		
Comorbidities related to autoimmune disorders^(a)			0.0093*
Reported	3.1	1.3-7.4	
Not reported	1(Ref)		
Complications (Ref = no complication)			
Abdominal pain	1.67	0.35-4.95	0.48
Chest radiograph (abnormal findings)	5.4	1.1-97.7	0.102
Dry cough	2.57	0.97-6.92	0.0532
Fever (>38 °C)	1.79	0.72-4.63	0.21
Myalgia fatigue	2.26	0.69-7.11	0.1662
Nausea	2.48	0.67-7.62	0.132
Productive cough	1.77	0.56-4.87	0.29
Runny nose	0.94	0.15-3.45	0.93
Sore throat	1.18	0.37-3.34	0.76
Vomiting	2.1	0.45-7.1	0.28
Treatment Option			
Not given a specific drug regimen	0.07	0.011-0.25	0.0005*
Given a specific drug regimen	1(Ref)		
Azithromycin	3.5	0.819-10.4	0.045*


Not given	1(Ref)		
HCQ	1.52	0.24-5.23	0.575
Not given	1(Ref)		
Interferon	0	0-154	0.993
Not given	1(Ref)		
lopinavir/ritonavir	19.28	0.98-130.4	0.0008*
Not given	1(Ref)		
Azithromycin + HCQ	2.21	0.93-5.32	0.071
Not given	1(Ref)		
lopinavir/ritonavir + Ribavirin	0	0-50.7	0.997
Not given	1(Ref)		
Azithromycin + HCQ + lopinavir/ritonavir	149.6	5.8-3808.4	0.0004*
Not given	1(Ref)		
Pneumonia Treatment	9.1	3.28-32.3	0.0001*
Not given	1(Ref)		
Combination Therapy (2 or more)	2.7	1.1-6.6	0.026*
Not given	1(Ref)		
Received mechanical ventilation	90	18.4-1624.2	<0.0001*
Not received	1(Ref)		

534 Abbreviation: BMI, body mass index; HCQ, Hydroxychloroquine


535 ^aComorbidity linked to immunity dysfunction including diabetes, rheumatoid, lupus IBS, and





536 APS

537 *Significant P-value less than 0.05.




medRxiv preprint doi: <https://doi.org/10.1101/2021.07.13.21260428>; this version posted July 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).





Age Groups



medRxiv preprint doi: <https://doi.org/10.1101/2021.07.13.21260428>; this version posted July 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.